Vaccinex, Inc. (VCNX)
OTCMKTS
· Delayed Price · Currency is USD
1.210
+0.200 (19.80%)
Dec 20, 2024, 4:00 PM EST
Vaccinex Revenue
Vaccinex had revenue of $52.00K in the quarter ending September 30, 2024, with 160.00% growth. This brings the company's revenue in the last twelve months to $388.00K, down -51.19% year-over-year. In the year 2023, Vaccinex had annual revenue of $570.00K with 107.27% growth.
Revenue (ttm)
388.00K
Revenue Growth
-51.19%
P/S Ratio
4.82
Revenue / Employee
9.95K
Employees
40
Market Cap
3.24M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
Vaccinex News
- 4 days ago - Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? - Benzinga
- 4 weeks ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 6 weeks ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire
- 7 weeks ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire
- 3 months ago - Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewsWire
- 4 months ago - Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership - GlobeNewsWire
- 5 months ago - Vaccinex stock tanks 40% despite positive Alzheimer's study update - Invezz